T. Nayak, Farooqui Shazia Parveen, M. Ahad, S. Bano
{"title":"Clinical Evaluation of Unani formulation in Gastritis- A Pilot Study","authors":"T. Nayak, Farooqui Shazia Parveen, M. Ahad, S. Bano","doi":"10.31254/jahm.2021.7310","DOIUrl":null,"url":null,"abstract":"Background and objectives: Gastritis is a painful or inflammatory state of the stomach and the mucosa covering it. The most common cause of gastritis is helicobacter pylorus. It is caused by certain infection, or by the routine use of antiinflammatory painkiller. Unani Physician has identified various medicinal products in classical text indicated for the treatment of gastritis. Therefore, a clinical trial was conducted to evaluate the clinical efficacy and safety of Unani Formulation in gastritis on scientific parameters. Methods: The study was designed as single blind pilot study on 12 patients of gastritis. Unani Formulation (Amla-2 part, Asl-Us-Soos-2 part, and Badiyan-2part) was given in the form of powder at the dose of 6 g twice a day after meal for the period of 28 days. All the patients of were assessed weekly on subjective parameters (at 0, 7th, 14th , 21th, and 28th day) whereas objective parameters were assessed before and after the treatment. The outcome of intervention was analyzed using appropriate statistical methods. Results: The study effects on subjective parameters like pain in abdomen, epigastric burning, nausea & vomiting and early satiety were found significantly reduced significantly. The objective parameter VAS and 5 PLS was found highly significant when compared before and after with p<0.0001. The results were analyzed after using paired ‘t’ test. Interpretation & Conclusion: The findings about the both parameters (subjective and objective) that the ‘Unani Formulation is effective gastritis and the cure was significant. Safety parameters (SGOT, SGPT, Blood Urea and Serum Creatinine) were remains unchanged. Therefore, it can be concluded that the Unani Formulation is safe and effective in management of gastritis.","PeriodicalId":15252,"journal":{"name":"Journal of Ayurvedic and Herbal Medicine","volume":"12 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ayurvedic and Herbal Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31254/jahm.2021.7310","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objectives: Gastritis is a painful or inflammatory state of the stomach and the mucosa covering it. The most common cause of gastritis is helicobacter pylorus. It is caused by certain infection, or by the routine use of antiinflammatory painkiller. Unani Physician has identified various medicinal products in classical text indicated for the treatment of gastritis. Therefore, a clinical trial was conducted to evaluate the clinical efficacy and safety of Unani Formulation in gastritis on scientific parameters. Methods: The study was designed as single blind pilot study on 12 patients of gastritis. Unani Formulation (Amla-2 part, Asl-Us-Soos-2 part, and Badiyan-2part) was given in the form of powder at the dose of 6 g twice a day after meal for the period of 28 days. All the patients of were assessed weekly on subjective parameters (at 0, 7th, 14th , 21th, and 28th day) whereas objective parameters were assessed before and after the treatment. The outcome of intervention was analyzed using appropriate statistical methods. Results: The study effects on subjective parameters like pain in abdomen, epigastric burning, nausea & vomiting and early satiety were found significantly reduced significantly. The objective parameter VAS and 5 PLS was found highly significant when compared before and after with p<0.0001. The results were analyzed after using paired ‘t’ test. Interpretation & Conclusion: The findings about the both parameters (subjective and objective) that the ‘Unani Formulation is effective gastritis and the cure was significant. Safety parameters (SGOT, SGPT, Blood Urea and Serum Creatinine) were remains unchanged. Therefore, it can be concluded that the Unani Formulation is safe and effective in management of gastritis.
背景和目的:胃炎是胃及其粘膜的疼痛或炎症状态。胃炎最常见的病因是幽门螺杆菌。它是由某种感染或常规使用抗炎止痛药引起的。乌纳尼医师在经典文献中确定了用于治疗胃炎的各种药物。为此,本研究通过科学参数评价乌尼方治疗胃炎的临床疗效和安全性。方法:采用单盲先导研究方法,对12例胃炎患者进行研究。乌拉尼制剂(Amla-2部分、asl - us - sos -2部分、巴地炎2部分)为粉剂,剂量为6 g,每日2次,餐后给药,连用28天。所有患者在治疗前和治疗后进行每周一次的主观参数评估(第0、7、14、21、28天),客观参数评估。采用适当的统计学方法对干预结果进行分析。结果:研究对腹部疼痛、上腹部烧灼感、恶心呕吐、早期饱腹感等主观参数的影响明显降低。客观参数VAS和5 PLS与前后比较,p<0.0001,具有高度显著性。采用配对t检验对结果进行分析。解释与结论:乌尼方对胃炎有效,治疗效果显著。安全性参数(SGOT、SGPT、尿素和血清肌酐)保持不变。由此可见,乌尼尼方治疗胃炎安全有效。